Prevalence and Disease Expression of Pathogenic and Likely Pathogenic Variants Associated With Inherited Cardiomyopathies in the General Population.


Journal

Circulation. Genomic and precision medicine
ISSN: 2574-8300
Titre abrégé: Circ Genom Precis Med
Pays: United States
ID NLM: 101714113

Informations de publication

Date de publication:
12 2022
Historique:
pubmed: 21 10 2022
medline: 23 12 2022
entrez: 20 10 2022
Statut: ppublish

Résumé

Pathogenic and likely pathogenic variants associated with arrhythmogenic right ventricular cardiomyopathy (ARVC), dilated cardiomyopathy (DCM), and hypertrophic cardiomyopathy (HCM) are recommended to be reported as secondary findings in genome sequencing studies. This provides opportunities for early diagnosis, but also fuels uncertainty in variant carriers (G+), since disease penetrance is incomplete. We assessed the prevalence and disease expression of G+ in the general population. We identified pathogenic and likely pathogenic variants associated with ARVC, DCM and/or HCM in 200 643 UK Biobank individuals, who underwent whole exome sequencing. We calculated the prevalence of G+ and analyzed the frequency of cardiomyopathy/heart failure diagnosis. In undiagnosed individuals, we analyzed early signs of disease expression using available electrocardiography and cardiac magnetic resonance imaging data. We found a prevalence of 1:578, 1:251, and 1:149 for pathogenic and likely pathogenic variants associated with ARVC, DCM and HCM respectively. Compared with controls, cardiovascular mortality was higher in DCM G+ (odds ratio 1.67 [95% CI 1.04; 2.59], In the general population, pathogenic and likely pathogenic variants associated with ARVC, DCM, or HCM are not uncommon. Although G+ have increased mortality and morbidity, disease penetrance in these carriers from the general population remains low (1.2-3.1%). Follow-up decisions in case of incidental findings should not be based solely on a variant, but on multiple factors, including family history and disease expression.

Sections du résumé

BACKGROUND
Pathogenic and likely pathogenic variants associated with arrhythmogenic right ventricular cardiomyopathy (ARVC), dilated cardiomyopathy (DCM), and hypertrophic cardiomyopathy (HCM) are recommended to be reported as secondary findings in genome sequencing studies. This provides opportunities for early diagnosis, but also fuels uncertainty in variant carriers (G+), since disease penetrance is incomplete. We assessed the prevalence and disease expression of G+ in the general population.
METHODS
We identified pathogenic and likely pathogenic variants associated with ARVC, DCM and/or HCM in 200 643 UK Biobank individuals, who underwent whole exome sequencing. We calculated the prevalence of G+ and analyzed the frequency of cardiomyopathy/heart failure diagnosis. In undiagnosed individuals, we analyzed early signs of disease expression using available electrocardiography and cardiac magnetic resonance imaging data.
RESULTS
We found a prevalence of 1:578, 1:251, and 1:149 for pathogenic and likely pathogenic variants associated with ARVC, DCM and HCM respectively. Compared with controls, cardiovascular mortality was higher in DCM G+ (odds ratio 1.67 [95% CI 1.04; 2.59],
CONCLUSIONS
In the general population, pathogenic and likely pathogenic variants associated with ARVC, DCM, or HCM are not uncommon. Although G+ have increased mortality and morbidity, disease penetrance in these carriers from the general population remains low (1.2-3.1%). Follow-up decisions in case of incidental findings should not be based solely on a variant, but on multiple factors, including family history and disease expression.

Identifiants

pubmed: 36264615
doi: 10.1161/CIRCGEN.122.003704
pmc: PMC9770140
mid: EMS155349
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e003704

Subventions

Organisme : Department of Health
ID : IS-BRC-1215-20016
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/18/50/33837
Pays : United Kingdom

Références

JAMA Cardiol. 2020 Jan 1;5(1):73-80
pubmed: 31774458
Nat Rev Cardiol. 2021 Jan;18(1):22-36
pubmed: 32895535
Eur J Hum Genet. 2018 Sep;26(9):1312-1318
pubmed: 29802319
Eur Heart J. 2012 Aug;33(15):1942-53
pubmed: 22240500
Clin Res Cardiol. 2017 Feb;106(2):127-139
pubmed: 27576561
Circ Heart Fail. 2009 May;2(3):253-61
pubmed: 19808347
Rev Esp Cardiol (Engl Ed). 2016 Feb;69(2):149-58
pubmed: 26507537
Circ Genom Precis Med. 2019 Feb;12(2):e002460
pubmed: 30681346
Circ Genom Precis Med. 2021 Jun;14(3):e003273
pubmed: 33831308
Circ Genom Precis Med. 2019 Nov;12(11):e002579
pubmed: 31638835
Am J Med Genet A. 2009 Feb 15;149A(4):602-12
pubmed: 19253387
Circulation. 2010 Apr 6;121(13):1533-41
pubmed: 20172911
Circulation. 2011 Dec 13;124(24):2761-96
pubmed: 22068435
J Am Coll Cardiol. 2021 Sep 14;78(11):1097-1110
pubmed: 34503678
Genet Med. 2017 Nov;19(11):1245-1252
pubmed: 28471438
Am J Hum Genet. 2012 Sep 7;91(3):513-9
pubmed: 22958901
Nat Genet. 2017 Jan;49(1):46-53
pubmed: 27869827
J Am Coll Cardiol. 2018 Nov 13;72(20):2471-2481
pubmed: 30442290
Circ Genom Precis Med. 2018 Apr;11(4):e001896
pubmed: 29661763
Genet Med. 2021 Aug;23(8):1381-1390
pubmed: 34012068
Circulation. 1980 Nov;62(5):1054-61
pubmed: 7418156
Front Public Health. 2021 Jul 01;9:697381
pubmed: 34277554
Nat Rev Cardiol. 2013 Sep;10(9):531-47
pubmed: 23900355
JACC Cardiovasc Imaging. 2020 Mar;13(3):684-695
pubmed: 31326477
Nat Rev Genet. 2011 Sep 27;12(11):745-55
pubmed: 21946919
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
PLoS One. 2015 Dec 23;10(12):e0145284
pubmed: 26701604
Circulation. 2021 Jul 6;144(1):7-19
pubmed: 33947203
Am J Hum Genet. 2017 Jun 1;100(6):895-906
pubmed: 28552198
J Cardiovasc Magn Reson. 2016 Feb 01;18:8
pubmed: 26830817
J Am Coll Cardiol. 2020 Dec 22;76(25):3022-3055
pubmed: 33229115
Nat Genet. 2021 Jul;53(7):942-948
pubmed: 34183854
Circulation. 2002 Jan 29;105(4):539-42
pubmed: 11815441
Circ Cardiovasc Genet. 2015 Jun;8(3):437-46
pubmed: 25820315
N Engl J Med. 2012 Feb 16;366(7):619-28
pubmed: 22335739
Circ Genom Precis Med. 2020 Jun;13(3):e002783
pubmed: 32163302
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669

Auteurs

Mimount Bourfiss (M)

Dept of Cardiology, Univ Medical Center Utrecht, Utrecht Univ, Utrecht, the Netherlands (M.B., M.v.V., A.I.A., A.S.J.M.t.R., B.R., J.v.S., A.F.S., F.W.A.).

Marion van Vugt (M)

Dept of Cardiology, Univ Medical Center Utrecht, Utrecht Univ, Utrecht, the Netherlands (M.B., M.v.V., A.I.A., A.S.J.M.t.R., B.R., J.v.S., A.F.S., F.W.A.).

Abdulrahman I Alasiri (AI)

Dept of Cardiology, Univ Medical Center Utrecht, Utrecht Univ, Utrecht, the Netherlands (M.B., M.v.V., A.I.A., A.S.J.M.t.R., B.R., J.v.S., A.F.S., F.W.A.).

Bram Ruijsink (B)

Dept of Cardiology, Univ Medical Center Utrecht, Utrecht Univ, Utrecht, the Netherlands (M.B., M.v.V., A.I.A., A.S.J.M.t.R., B.R., J.v.S., A.F.S., F.W.A.).
School of Biomedical Engineering & Imaging Sciences, King's College London, London, United Kingdom (B.R., E.P.-A.).

Jessica van Setten (J)

Dept of Cardiology, Univ Medical Center Utrecht, Utrecht Univ, Utrecht, the Netherlands (M.B., M.v.V., A.I.A., A.S.J.M.t.R., B.R., J.v.S., A.F.S., F.W.A.).

A Floriaan Schmidt (AF)

Dept of Cardiology, Univ Medical Center Utrecht, Utrecht Univ, Utrecht, the Netherlands (M.B., M.v.V., A.I.A., A.S.J.M.t.R., B.R., J.v.S., A.F.S., F.W.A.).
Faculty of Population Health Sciences Institute of Cardiovascular Science, London, London, United Kingdom (A.F.S., F.W.A.).

Dennis Dooijes (D)

Dept of Genetics, Univ Medical Center Utrecht, Utrecht Univ, Utrecht, the Netherlands (D.D., J.P.v.T., A.F.B.).

Esther Puyol-Antón (E)

School of Biomedical Engineering & Imaging Sciences, King's College London, London, United Kingdom (B.R., E.P.-A.).

Birgitta K Velthuis (BK)

Dept of Radiology, Univ Medical Center Utrecht, Utrecht Univ, Utrecht, the Netherlands (B.K.V.).

J Peter van Tintelen (JP)

Dept of Genetics, Univ Medical Center Utrecht, Utrecht Univ, Utrecht, the Netherlands (D.D., J.P.v.T., A.F.B.).

Anneline S J M Te Riele (ASJM)

Dept of Cardiology, Univ Medical Center Utrecht, Utrecht Univ, Utrecht, the Netherlands (M.B., M.v.V., A.I.A., A.S.J.M.t.R., B.R., J.v.S., A.F.S., F.W.A.).
Netherlands Heart Institute, Utrecht, the Netherlands (A.S.J.M.t.R).

Annette F Baas (AF)

Dept of Genetics, Univ Medical Center Utrecht, Utrecht Univ, Utrecht, the Netherlands (D.D., J.P.v.T., A.F.B.).

Folkert W Asselbergs (FW)

Dept of Cardiology, Univ Medical Center Utrecht, Utrecht Univ, Utrecht, the Netherlands (M.B., M.v.V., A.I.A., A.S.J.M.t.R., B.R., J.v.S., A.F.S., F.W.A.).
Faculty of Population Health Sciences Institute of Cardiovascular Science, London, London, United Kingdom (A.F.S., F.W.A.).
Health Data Research UK & Institute of Health Informatics, Univ College London, London, United Kingdom (F.W.A.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH